Why the study?
Does myostatin blockade with mRK35 or domagrozumab increase muscle mass and improve muscle function in preclinical models of Duchenne muscular dystrophy and non-human primates?
Population
Normal mice, mdx mice (model of Duchenne muscular dystrophy), and non-human primates (cynomolgus monkeys)
Design
Preclinical
Authors
Loading...
Supports myostatin inhibition for muscle mass in DMD; leaves open functional benefits and broad applicability.
Does myostatin blockade with mRK35 or domagrozumab increase muscle mass and improve muscle function in preclinical models of Duchenne muscular dystrophy and non-human primates?
The anti-myostatin antibodies mRK35 and domagrozumab induce muscle anabolic activity and improve muscle strength in preclinical models, supporting their clinical investigation for Duchenne muscular dystrophy.
Andre et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: